(S1 (S (NP (NP (NN Relationship)) (PP (IN of) (NP (NP (JJ cellular) (NN immunity)) (, ,) (NP (NNS cytokines)) (CC and) (NP (NN CRP)))) (PP (IN with) (NP (NP (JJ clinical) (NN course)) (PP (IN in) (NP (NP (NN breast) (NN cancer) (NNS patients)) (PP (IN with) (NP (NP (JJ endocrine-dependent) (JJ distant) (NNS metastases)) (VP (VBN treated) (PP (IN with) (NP (NN immunotherapy)))))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN reported) (NP (NP (JJ important) (NNS benefits)) (CC and) (NP (NN survival))) (PP (IN with) (NP (NP (DT an) (NN immunotherapy) (NN schedule)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ endocrine-dependent) (NN breast) (NN cancer)) (CC and) (NP (JJ distant) (NNS metastases))))))))))) (. .)))
(S1 (S (S (S (NP (RB Here) (JJ clinical) (NN outcome)) (VP (VBZ is) (VP (VBN updated)))) (CC and) (S (NP (NP (PRP$ its) (NN correlation)) (PP (IN with) (NP (JJ new) (JJ immunological) (NNS data)))) (VP (VBZ is) (VP (VBN shown))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (CD 32) (NP (VBN evaluated) (NN breast) (NN cancer) (NNS patients))) (PP (IN with) (NP (JJ endocrine-dependent) (JJ distant) (NNS metastases))) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ new) (NN immunotherapy) (NN schedule)) (PRN (-LRB- -LRB-) (NP (NP (JJ cyclic) (NN administration)) (PP (IN of) (NP (NP (NN beta-interferon)) (CC and) (NP (NN interleukin-2))))) (-RRB- -RRB-))))))) (, ,) (NP (NP (JJ cellular) (NN immunity)) (, ,) (NP (NNS cytokines)) (CC and) (NP (NN CRP))) (VP (VBD were) (ADJP (JJ related) (PP (TO to) (NP (DT the) (JJ clinical) (NN course)))))) (. .)))
(S1 (S (S (NP (NP (ADJP (ADJP (VBN Estimated)) (CC and) (ADJP (JJ true))) (ADJP (CD 5-10) (NN year)) (JJ overall) (NN survival) (NNS rates)) (PP (IN from) (NP (NP (JJ first) (NN line) (NN antiestrogen)) (CC and) (NP (JJ distant) (NNS metastases))))) (VP (VBD were) (ADJP (ADJP (JJR higher)) (SBAR (IN than) (S (ADVP (RB previously)) (VP (VBN reported) (PP (IN in) (NP (DT a) (JJ similar) (NN population))))))))) (. .)))
(S1 (S (S (NP (NN Interleukin-2) (NN administration)) (VP (VBD was) (VP (VBN followed) (PP (IN by) (NP (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (JJ total) (NNS lymphocytes)) (, ,) (ADJP (ADJP (JJ CD4+)) (, ,) (ADJP (JJ CD8+))) (, ,) (NP (JJ CD16+56+) (-LRB- -LRB-) (NN NK) (-RRB- -RRB-) (NNS cells)) (, ,) (NP (NP (NP (NN IL-6)) (, ,) (NP (NN IL-12)) (, ,) (CC and) (NP (NN CRP))) (PRN (-LRB- -LRB-) (PP (IN from) (NP (NP (NN P) (NN <) (CD 0.04)) (PP (TO to) (NP (NN P) (NN <) (NN 0.000))))) (-RRB- -RRB-)))))) (CC but) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (NN IL-10)) (CC and) (NP (NN TGFbeta1)))) (PP (IN during) (NP (JJ clinical) (NN benefit))))))))) (. .)))
(S1 (S (S (PP (IN During) (NP (JJ progressive) (NN disease))) (NP (DT no) (NN change)) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ former) (NNS parameters))) (, ,) (S (ADJP (JJ concomitant) (PP (IN with) (NP (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NN IL-10)) (PRN (-LRB- -LRB-) (NP (NN P=0.020)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (NN TGFbeta1)) (PRN (-LRB- -LRB-) (NP (NN P=0.023)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VBP confirm) (SBAR (IN that) (S (NP (JJ cellular) (NN immunity)) (VP (VBZ is) (ADVP (RB significantly)) (VP (VBN stimulated) (PP (IN by) (NP (NN IL-2))) (PP (ADVP (RB only)) (IN during) (NP (JJ clinical) (NN benefit))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (DT these) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (JJ different) (NNS changes)) (PP (IN of) (NP (NP (JJ proinflammatory) (NNS cytokines)) (, ,) (NP (NN CRP)) (CC and) (NP (NN inhibiting) (NNS factors))))) (VP (VBP are) (ADJP (JJ consistent) (PP (PP (IN with) (NP (JJ associated) (JJ clinical) (NN benefit))) (CC or) (PP (IN with) (NP (NN disease) (NN progression)))) (, ,) (ADVP (RB respectively)))))))) (. .)))
